Skin Cancer: Mistake to avoid during the winter months to prevent the disease - expert
SKIN cancer is one of the most common cancers worldwide, with 147,000 new cases of non-melanoma skin cancer diagnosed in the UK every year. Express.co.uk spoke to a skin expert about a mistake to avoid that could lead to this condition even in winter. (Source: Daily Express - Health)
Source: Daily Express - Health - December 4, 2021 Category: Consumer Health News Source Type: news

FDA approves pembrolizumab for adjuvant treatment of Stage IIB or IIC melanoma  
On December 3,2021, the Food and Drug Administration  approved pembrolizumab (Keytruda, Merck) for the adjuvant treatment of adult and pediatric (≥12 years of age) patients with stage IIB or IIC melanoma following complete resection. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - December 3, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Differences in Response to Immunotherapy in Men vs Women Differences in Response to Immunotherapy in Men vs Women
Women with advanced melanoma had a twofold increase in mortality risk, compared with male counterparts, when treated with combination checkpoint inhibition.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 2, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Triplet Regimen Boosts Survival in Metastatic Melanoma, but at a Cost Triplet Regimen Boosts Survival in Metastatic Melanoma, but at a Cost
For patients with metastatic melanoma, triplet therapy with atezolizumab and vemurafenib plus cobimetinib provides significant survival benefits, but the regimen may not be cost-effective, researchers say.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 25, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

The Time of Day of Immunotherapy Infusions Affects Survival The Time of Day of Immunotherapy Infusions Affects Survival
A new study reveals that giving immunotherapy infusions earlier in the day leads to better overall survival for patients with advanced melanoma.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 22, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

UCLA scientists make strides toward an ‘off-the-shelf’ immune cell therapy for cancer
Immunotherapies, which harness the body ’s natural defenses to combat disease, have revolutionized the treatment of aggressive and deadly cancers. But often, these therapies — especially those based on immune cells — must be tailored to the individual patient, costing valuable time and pushing their price into the hundreds of thousa nds of dollars.Now, in a study published in the journal Cell Reports Medicine, UCLA researchers report a critical step forward in the development of an “off-the-shelf” cancer immunotherapy using rare but powerful immune cells that could potentially be produced...
Source: UCLA Newsroom: Health Sciences - November 16, 2021 Category: Universities & Medical Training Source Type: news

T2DM and Markers of Cutaneous Melanoma Aggressiveness T2DM and Markers of Cutaneous Melanoma Aggressiveness
This study investigated a possible relationship between type 2 diabetes mellitus and an increased incidence and/or aggressiveness of melanoma, with or without metformin therapy.The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 10, 2021 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline du...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Skin Checks Reduce All-Cause but Not Melanoma-Specific Deaths Skin Checks Reduce All-Cause but Not Melanoma-Specific Deaths
The findings are based on a study conducted in Australia, which assessed melanoma-specific and all-cause mortality associated with melanoma identified through routine skin checks.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - November 3, 2021 Category: Internal Medicine Tags: Dermatology News Source Type: news

All - Cause Mortality Lower for Melanomas ID ’ d in Routine Skin Checks
After adjustment for prognostic factors, no association seen between detection by routine skin check and melanoma - specific mortality (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - November 3, 2021 Category: Cancer & Oncology Tags: Dermatology, Family Medicine, Internal Medicine, Oncology, Pathology, Journal, Source Type: news

PET tracer proves effective for assessing immunotherapy
PET imaging can show whether patients with melanoma or non-small cell lung cance...Read more on AuntMinnie.comRelated Reading: U.S. cancer care financial burden hit $21B in 2019 New PET radiotracer more effective at detecting cancer PET tracer predicts response to immunotherapy AI can lend a hand in diagnosis, prognosis of oral SCC PET/CT shows promise predicting outcomes in head, neck cancer (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - November 3, 2021 Category: Radiology Source Type: news

Study Supports Opdivo as Second-Line Mesothelioma Treatment
When the effectiveness of first-line chemotherapy fails and malignant mesothelioma returns, more patients could soon turn with confidence to a proven, second-line treatment. The first phase III, placebo-controlled, double-blind clinical trial studying the safety and efficacy of Opdivo, the immunotherapy drug known generically as nivolumab, has raised the level of confidence in this option for patients with relapsed disease. “The evidence is robust, the survival significant,” Dr. Dean Fennell, chair of Thoracic Medical Oncology, University of Leicester and University Hospitals in the United Kingdom, told T...
Source: Asbestos and Mesothelioma News - November 2, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

A Review and Call for More Research Into Nodular Melanoma A Review and Call for More Research Into Nodular Melanoma
This paper highlights the distinct characteristics of nodular melanoma, an aggressive subtype associated with poor survival.The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 27, 2021 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

Fecal Transplants May Improve Resistance to Melanoma Therapy Fecal Transplants May Improve Resistance to Melanoma Therapy
' The big question...is why and how does FMT work, and how can we make the response better?'asked Dr Teri Greiling of Oregon Health& Science University.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - October 21, 2021 Category: Gastroenterology Tags: Dermatology News Source Type: news

Skin Cancer App Fails to Identify Rare, Aggressive Cancers
Sensitivity and specificity for detecting Merkel cell carcinoma and amelanotic melanoma was 79.4 and 37.7 percent, respectively (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - October 14, 2021 Category: Cancer & Oncology Tags: Dermatology, Family Medicine, Internal Medicine, Oncology, Pathology, Conference News, Source Type: news

New Opdivo/Yervoy Mesothelioma Clinical Trial Begins Soon
A novel clinical trial involving the immunotherapy combination of Opdivo and Yervoy will open soon in Chicago. The goal is to study the drugs’ efficacy when added to surgery for patients with peritoneal mesothelioma cancer. The single-center, phase II clinical trial follows a recent report detailing the impressive three-year effectiveness of the drug combination when used for unresectable pleural mesothelioma. Bristol Myers Squibb manufactures Opdivo and Yervoy, known generically as nivolumab and ipilimumab. The U.S. Food and Drug Administration approved the combination for pleural mesothelioma in 2020, making ...
Source: Asbestos and Mesothelioma News - October 7, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Is Ocular Melanoma Same as Uveal Melanoma?
Title: Is Ocular Melanoma Same as Uveal Melanoma?Category: Diseases and ConditionsCreated: 10/4/2021 12:00:00 AMLast Editorial Review: 10/4/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - October 4, 2021 Category: Cancer & Oncology Source Type: news

Lithuanian Researchers Develop Novel Noninvasive Method for Diagnosing Melanoma That Has Greater than 90% Accuracy
Computer-aided diagnostic system combines optical dermatoscopy, spectrophotometry and high-frequency ultrasound imaging techniques to differentiate malignant lesions from benign moles Detecting skin cancer via the use of skin biopsies is the bread and butter of many dermatopathology practices. But new technologies that can instantly detect and distinguish different types of skin malignancies may result in a […] The post Lithuanian Researchers Develop Novel Noninvasive Method for Diagnosing Melanoma That Has Greater than 90% Accuracy appeared first on Dark Daily. (Source: Dark Daily)
Source: Dark Daily - September 29, 2021 Category: Laboratory Medicine Authors: Jillia Schlingman Tags: International Laboratory News Laboratory Instruments & Laboratory Equipment Laboratory Pathology Laboratory Testing Precision Medicine Abraham Katzir PhD anatomic pathology clinical laboratory clinical pathology Dark Daily dark intelli Source Type: news

Penn Medicine, Wistar Institute get $11.7M NCI grant to develop potential melanoma treatments
The National Cancer Institute (NCI) awarded Penn Medicine and The Wistar Institute $11.7 million to support melanoma research. The five-year award from the NCI's Specialized Programs of Research Excellence will be used to fund three new melanoma research projects. The projects will seek to translate laboratory discoveries made in the Perelman School of Medicine at the University of Pennsylvania and at The Wistar Institu te, both in West Philadelphia, into new therapeutics to treat skins cancers. Melanoma… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - September 24, 2021 Category: American Health Authors: John George Source Type: news

Survival Up With Tebentafusp in Metastatic Uveal Melanoma
Overall survival longer with tebentafusp for HLA*02:01 - positive patients with previously untreated metastatic uveal melanoma (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 23, 2021 Category: Cancer & Oncology Tags: Oncology, Ophthalmology, Pharmacy, Journal, Source Type: news

The Association Between Citrus Consumption and Melanoma Risk The Association Between Citrus Consumption and Melanoma Risk
Psoralen, a known photocarcinogen, is abundant in citrus products. Might consumption of citrus be associated with an increased risk of melanoma?The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 22, 2021 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

Adjuvant Pembrolizumab Cuts Recurrence in Stage II Melanoma
Compared with placebo, pembrolizumab prolonged regression - free survival in resected high - risk stage IIB and IIC melanoma (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 20, 2021 Category: Cancer & Oncology Tags: Dermatology, Oncology, Pharmacy, Conference News, Source Type: news

Salty Diet Helps Gut Bugs Fight Cancer in Mice: Study
A high-salt diet suppressed the growth of tumors in a mouse model of melanoma, apparently because of an interplay between the gut microbiome and natural killer cells. (Source: The Scientist)
Source: The Scientist - September 20, 2021 Category: Science Tags: News & Opinion Source Type: news

Adjuvant Pembro Success in Early Melanoma Raises Questions Adjuvant Pembro Success in Early Melanoma Raises Questions
Adjuvant pembrolizumab significantly improved recurrence-free survival in stage 2B/C melanoma in KEYNOTE 716, but which patients benefit most and what does this mean for treatment down the line?Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 19, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

How a plant virus could protect and save your lungs from metastatic cancer
Using a virus that grows in black-eyed pea plants, nanoengineers at the University of California San Diego developed a new treatment that could keep metastatic cancers at bay from the lungs. The treatment not only slowed tumor growth in the lungs of mice with either metastatic breast cancer or melanoma, it also prevented or drastically minimized the spread of these cancers to the lungs of healthy mice that were challenged with the disease. (Source: World Pharma News)
Source: World Pharma News - September 14, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

PET tracer predicts response to immunotherapy
An experimental PET radiotracer can predict whether patients will respond earl...Read more on AuntMinnie.comRelated Reading: PET identifies early responders to liver cancer treatment Second-look PET/CT catches cancer spread FDG-PET/CT aids in melanoma treatment assessment New PET tracer could aid melanoma detection MRI holds promise for immunotherapy but needs more research (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 14, 2021 Category: Radiology Source Type: news

Doctors identify an eye cancer culprit
Researchers have identified a molecular mechanism that drives the progression of uveal melanoma, an often lethal eye cancer in adults. (Source: Yale Science and Health News)
Source: Yale Science and Health News - September 13, 2021 Category: Universities & Medical Training Source Type: news

Melanoma Genomics: A Review of Practical Clinical Applications Melanoma Genomics: A Review of Practical Clinical Applications
How can recent advances in our understanding of the genetics, epigenetics, and genomics of melanoma inform modern melanoma diagnosis and treatment?The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 8, 2021 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

Cancer symptoms: An 'invasive' melanoma to spot on the palms or soles of the feet
SKIN cancer can penetrate deep into the layers of the skin, metastasising into other bodily organs. Such a deadly condition is known as melanoma. (Source: Daily Express - Health)
Source: Daily Express - Health - September 7, 2021 Category: Consumer Health News Source Type: news

Targeted and Immunotherapies in BRAF Mutant Melanoma Targeted and Immunotherapies in BRAF Mutant Melanoma
Review the clinical considerations for choosing between MAPK inhibitors and immune checkpoint inhibitors as first-line therapy for BRAF mutant advanced melanoma.The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 1, 2021 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

Med Students Lead Skin Cancer Screening, Education Event Med Students Lead Skin Cancer Screening, Education Event
This disparity is reflected in statistics showing that the average 5-year survival rate for melanoma is 92% in White patients but drops down to 67% in Black patients.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 31, 2021 Category: Consumer Health News Tags: Dermatology News Source Type: news

Spotting the Signs of Deadly Melanoma Skin Cancers
Title: Spotting the Signs of Deadly Melanoma Skin CancersCategory: Health NewsCreated: 8/22/2021 12:00:00 AMLast Editorial Review: 8/23/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - August 23, 2021 Category: Cancer & Oncology Source Type: news

Spotting the Signs of Deadly Melanoma Skin Cancers
SUNDAY, Aug. 22, 2021— Regular skin checks to look for signs of melanoma could save your life. Self-exams for the deadliest type of skin cancer should be done at least once a month in a well-lit room in front of a full-length mirror and also... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 22, 2021 Category: General Medicine Source Type: news

Previous Tx in Metastatic Melanoma May Cut Response to ACT TIL
Prior therapy linked to lower objective response rate to adoptive cell transfer with tumor - infiltrating lymphocytes compared with no prior therapy (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - August 19, 2021 Category: Cancer & Oncology Tags: Dermatology, Oncology, Pathology, Journal, Source Type: news

Previous Tx in Metastatic Melanoma May Cut Response to ACT TIL
THURSDAY, Aug. 19, 2021 -- Previous treatment with anti-programmed cell death-1 (aPD-1) therapy or targeted molecular therapy is associated with a lower objective response rate to adoptive cell transfer (ACT) of autologous tumor-infiltrating... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 19, 2021 Category: Pharmaceuticals Source Type: news

Certain Dermoscopic Structures Linked to Melanoma Detection
WEDNESDAY, Aug. 4, 2021 -- Certain dermoscopic structures associated with melanoma detection may have diagnostic importance, including shiny white structures, pseudopods, and blue-white veil, according to a systematic review and meta-analysis... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 4, 2021 Category: Pharmaceuticals Source Type: news

New Long-term Melanoma Data'Clearly Favor' IPI/NIVO New Long-term Melanoma Data'Clearly Favor' IPI/NIVO
Dr Jeffrey Weber discusses long-term follow-up data presented at ASCO 2021.Medscape Oncology (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - August 3, 2021 Category: Radiology Tags: Hematology-Oncology Commentary Source Type: news

US FDA grants Priority Review to Roche ’s Tecentriq as adjuvant treatment for certain people with early non-small cell lung cancer
Basel, 3 August 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company ’s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq® (atezolizumab) as adjuvant treatment following surgery and platinum-based chemotherapy for people with non-small cell lung cancer (NSCLC) whose tumours express PD-L1≥1%, as determined by an FDA-appro ved test. The FDA is reviewing the application under the Real-Time Oncology Review pilot programme, which aims to explore a more efficient review process to ensure safe and ef...
Source: Roche Media News - August 3, 2021 Category: Pharmaceuticals Source Type: news

US FDA grants Priority Review to Roche ’s Tecentriq as adjuvant treatment for certain people with early non-small cell lung cancer
Basel, 3 August 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company ’s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq® (atezolizumab) as adjuvant treatment following surgery and platinum-based chemotherapy for people with non-small cell lung cancer (NSCLC) whose tumours express PD-L1≥1%, as determined by an FDA-appro ved test. The FDA is reviewing the application under the Real-Time Oncology Review pilot programme, which aims to explore a more efficient review process to ensure safe and ef...
Source: Roche Investor Update - August 3, 2021 Category: Pharmaceuticals Source Type: news

Alkermes Receives FDA Fast Track Designation for Nemvaleukin Alfa for the Treatment of Mucosal Melanoma
DUBLIN, Aug. 2, 2021 -- (Healthcare Sales & Marketing Network) -- Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to nemvaleukin alfa (nemvaleukin), the company's novel, inves... Biopharmaceuticals, Oncology, FDA Alkermes, nemvaleukin, mucosal melanoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 2, 2021 Category: Pharmaceuticals Source Type: news

Almost Every Doctor Recommends Sunscreen. So Why Don ’t We Know More About Its Safety?
Each year, as Memorial Day approaches, Holly Thaggard braces herself for the headlines. About how sunscreen may be damaging coral reefs. About the possible flammability of spray-on sunscreen. Headlines—as there were this year—about how sunscreen contains chemicals that could harm your health. “This has happened every single year for the last decade of my life,” says Thaggard, founder of Texas-based Supergoop, a sunscreen company that brands itself as reef-safe and free of hundreds of potentially problematic ingredients. This year, the is-sunscreen-dangerous news cycle started in May, when Valisure, ...
Source: TIME: Health - August 2, 2021 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized healthscienceclimate Public Health Source Type: news

What's Next After Anti-PD-1 Therapy for Melanoma Fails? What's Next After Anti-PD-1 Therapy for Melanoma Fails?
Dr Jeffrey Weber describes two studies with encouraging results for patients with advanced melanoma that has not responded to anti-PD-1 and other immunotherapies.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 29, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

Eliminating RNA-binding protein improves survival in aggressive leukemia
Removing a protein that is often overexpressed in a rare and aggressive subtype of leukemia can help to slow the cancer ’s development and significantly increase the likelihood of survival, according to a study in mice led by scientists at theUCLA Jonsson Comprehensive Cancer Center.The research,published today in the journal Leukemia, could aid in the development of targeted therapies for cancers that have high levels of the RNA-binding protein IGF2BP3 — especially acute lymphoblastic and myeloid leukemias that are characterized by chromosomal rearrangements in the mixed lineage leukemia (MLL) gene.In these ML...
Source: UCLA Newsroom: Health Sciences - July 29, 2021 Category: Universities & Medical Training Source Type: news

ECU professor developing melanoma treatment nets $110K grant from NC Biotech
An ECU professor is assessing the commercial feasibility of the potential treatment for melanoma. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - July 22, 2021 Category: American Health Authors: Sonia Waraich Source Type: news

Antibiotics may help to treat melanoma
Some antibiotics appear to be effective against a form of skin cancer known as melanoma. Researchers at KU Leuven, Belgium, examined the effect of these antibiotics on patient-derived tumours in mice. Their findings were published in the Journal of Experimental Medicine. (Source: World Pharma News)
Source: World Pharma News - July 22, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Antibiotics may help to treat melanoma
(KU Leuven) Some antibiotics appear to be effective against a form of skin cancer known as melanoma. Researchers at KU Leuven, Belgium, examined the effect of these antibiotics on patient-derived tumours in mice. Their findings were published in the Journal of Experimental Medicine. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 22, 2021 Category: International Medicine & Public Health Source Type: news

Recent Trend: Melanoma Mortality Declining Rapidly Recent Trend: Melanoma Mortality Declining Rapidly
The drop in death rates has occurred despite increased incidence rates for both men and women.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 20, 2021 Category: Consumer Health News Tags: Dermatology News Source Type: news

Johnson & Johnson Consumer Inc. Issues Voluntary Recall of Specific NEUTROGENA ® and AVEENO® Aerosol Sunscreen Products Due to the Presence of Benzene
NEW BRUNSWICK, N.J., JULY 14, 2021 – Johnson & Johnson Consumer Inc. (JJCI) is voluntarily recalling all lots of five NEUTROGENA® and AVEENO® aerosol sunscreen product lines to the consumer level. Internal testing identified low levels of benzene in some samples of the products. Consumers should stop using the affected products and follow the instructions set forth below.The only sunscreen products impacted are aerosol products, specifically: NEUTROGENA® Beach Defense® aerosol sunscreen, NEUTROGENA® Cool Dry Sport aerosol sunscreen,NEUTROGENA® Invisible Daily™ defense aerosol sunscre...
Source: Johnson and Johnson - July 14, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

NSCLC and Melanoma Lead Continuing Fall in US Cancer Death Rates NSCLC and Melanoma Lead Continuing Fall in US Cancer Death Rates
Cancer death rates in the US continue to decline overall for many common cancers in both men and women, especially non –small cell lung cancer (NSCLC) and melanoma.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 14, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Risk Factors for Melanoma by Anatomical Site Risk Factors for Melanoma by Anatomical Site
Differing risk factors for melanoma by anatomical site, as found in this study, suggest a dual pathway for its pathogenesis.The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 14, 2021 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news